Q&As
Is CCR2b a target for lupus erythematosus?
A study based on computerized bioinformatics analysis suggests that CCR2 is a potential drug target for lupus erythematosus. The main basis is as follows:
(a) Included as CCLE-DEG (blood and skin) by microarray analysis. The observed upregulation in case vs. control (blood) and lesional vs. non-lesional (skin) are accompanied by low e-values of ≤ 0.05.
(b) Overexpressed in disease vs. control peripheral blood by RT-qPCR analysis, in a separate set of samples as those used in the microarray analysis.
(c) Enriched in lupus-related pathways and processes by ontology enrichment analyses.
(d) "Over-connected" functional molecule by interactome analysis.
(e) A reaction hub by network analysis.
(f) Mapped to chromosome 3 in an overlapping skin/blood transcriptional "hot spot" by chromosome mapping analysis.
(g) Targeted by drugs that are currently being used to treat other diseases such as inflammatory and immune diseases by drug target analysis.
2022-12-13
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
Related Products